Work Here?
Overview
Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.
About Cellanome
Industries
Data & Analytics
Enterprise Software
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$276.9M
Headquarters
Foster City, California
Founded
2020
Get referred to Cellanome
See people who can refer or advise you
Simplify's Take
What believers are saying
- Psomagen added the R3200 on March 26, 2026, validating external demand.
- Cellanome showcased live-cell analysis marrying imaging and sequencing at AGBT 2026.
- Cellanome raised $75.9 million on June 22, 2026, extending runway.
What critics are saying
- 10x Genomics and other single-cell vendors already dominate adjacent workflows.
- Cellanome still lacks proof of broad customer adoption beyond Psomagen and conferences.
- If 2026 spending misses hardware sales, the platform becomes an expensive science project.
What makes Cellanome unique
- Cellanome links longitudinal live-cell imaging to single-cell transcriptomics from the same cells.
- Its CellCage micro-3D-printed enclosures isolate cells while drugs and antibodies flow.
- R3200 captures morphology, phenotype, and RNA on identical live cells.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$276.9M
Above
Industry Average
Funded Over
4 Rounds
Industry standards
Benefits
Health Insurance
Stock Options
401(k) Retirement Plan
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 58%2 year growth
↑ 0%EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659
Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.
A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.
Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.
Cellanome is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Cellanome
Industries
Data & Analytics
Enterprise Software
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$276.9M
Headquarters
Foster City, California
Founded
2020
Cellanome is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today